Nkarta(NKTX) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights SOUTH SAN FRANCISCO, Calif., May 9, 2024 -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter ended March 31, 2024. • In March 2024, Nkarta completed an underwritten offering of common stock and pre-funded warrants with gross proceeds of $240.1 million. New and existing investors partic ...